ADHD in Primary Care: Assessment Across Ages, Stimulant Choice, Monitoring and Controlled-Substance Rules

ADHD is a primary care diagnosis made from DSM-5 criteria, information from more than one setting and a screen for conditions that mimic or coexist with it. The AAP 2019 guideline tells the provider to evaluate any child or adolescent aged 4 to 18 with academic or behavioral problems and symptoms of inattention, hyperactivity or impulsivity, then to treat by age: parent training in behavior management first for preschoolers, and FDA-approved medication with behavioral and school supports from age 6. In adults, stimulants are the usual first-line drugs, and because they are Schedule II, prescribing follows DEA rules that the exam tests directly.

Assessment across ages

DSM-5 criteria

• Symptom count. At least six symptoms of inattention and/or six of hyperactivity-impulsivity for at least 6 months, inconsistent with developmental level. From age 17, five symptoms in a domain are enough.
• Onset. Several symptoms present before age 12.
• Pervasiveness. Several symptoms present in two or more settings (home, school, work, social).
• Impairment. Clear interference with social, academic or occupational functioning.
• Exclusion. Not better explained by another mental disorder, and not only during psychosis.
• Presentations. Predominantly inattentive, predominantly hyperactive-impulsive, or combined, with severity rated mild, moderate or severe.

Children and adolescents (AAP 2019)

The AAP guideline asks the provider to gather reports from parents or guardians, teachers and other school personnel, and mental health clinicians involved in the child's care, usually through validated rating scales such as the Vanderbilt scales. For adolescents, collect information from at least two teachers and from the adolescent, because symptoms are often less visible and substance use and other conditions become more likely.

The evaluation must also screen for coexisting conditions: emotional and behavioral (anxiety, depression, oppositional defiant disorder, conduct disorder, substance use), developmental (learning and language disorders, autism spectrum disorder) and physical (tics, sleep apnea). A hearing and vision check and a sleep history belong in every evaluation.

Adults

Adult ADHD requires the same DSM-5 criteria, including evidence that symptoms began before 12, which usually means collateral history from a parent or partner and old school records. The 6-item WHO Adult ADHD Self-Report Scale (ASRS v1.1) screener is the common primary care entry tool; four or more responses in the shaded boxes is a positive screen that leads to a full diagnostic interview, not a diagnosis.

Adult differentials to rule out before prescribing a stimulant:

• Depression, anxiety and bipolar disorder (a bipolar history changes the plan).
• Substance use disorders, including current stimulant misuse.
• Sleep disorders, especially obstructive sleep apnea and chronic sleep deprivation.
• Thyroid disease and medication effects.
• Requests driven by performance pressure rather than lifelong impairment.

Cardiac screening

Before a stimulant, ask about fainting or chest pain with exercise, palpitations, known heart disease, and family history of sudden or unexplained death at a young age, cardiomyopathy or inherited arrhythmia. Measure blood pressure and heart rate and examine the heart. A routine ECG is not required for every patient; a positive history or abnormal examination calls for an ECG or cardiology evaluation first.

Treatment by age

The AAP also directs the provider to titrate medication to the dose that gives maximum benefit with tolerable adverse effects, and to treat ADHD as a chronic condition using the chronic care model and medical home.

Choosing the drug

Stimulant versus nonstimulant

Practical prescribing

• Start low and titrate. Begin at the lowest dose of the chosen formulation and increase about weekly based on parent, teacher or patient reports and adverse effects, aiming for the AAP target of maximum benefit with tolerable adverse effects. Confirm specific milligram doses against current labeling.
• Long-acting formulations improve coverage through the school day and homework, avoid in-school dosing and reduce misuse because they are harder to tamper with.
• If one stimulant class fails, try the other class (methylphenidate to amphetamine or the reverse) before abandoning stimulants.
• Boxed warning. Stimulants carry a boxed warning for abuse, misuse and addiction. Assess misuse risk before starting and periodically, and counsel on safe storage and never sharing.
• Avoid or use extreme caution with MAOI use within 14 days, known structural heart disease or serious arrhythmia, uncontrolled hypertension, current stimulant use disorder, and untreated bipolar disorder or psychosis.

Monitoring

During titration, contact is usually every 1 to 2 weeks, then at least every few months once stable; state rules for controlled substances may require more frequent visits. Drug holidays on weekends or summers can be discussed when growth is a concern.

Controlled-substance rules

Federal Schedule II rules

• No refills. A Schedule II prescription cannot be refilled (21 CFR 1306.12(a)).
• Multiple prescriptions. On the same day, the prescriber may issue several prescriptions totaling up to a 90-day supply, each after the first marked with the earliest date it may be filled, provided the practice is medically appropriate and permitted by state law (21 CFR 1306.12(b)).
• Electronic prescribing. Electronic prescriptions for controlled substances are allowed when the prescriber and pharmacy systems meet DEA requirements, and many states mandate it.
• DEA registration. The prescriber needs a DEA registration that includes Schedule II in each state where they prescribe, and the state must grant the NP Schedule II authority.

State rules vary

Some states limit NP Schedule II prescribing (for example by supply length, a collaborative agreement or a physician co-signature), require PDMP checks at set intervals or require controlled-substance agreements. The exam expects awareness that state law can be stricter than federal law, and that the stricter rule applies.

Telemedicine

The Ryan Haight Act generally requires an in-person medical evaluation before a controlled substance is prescribed through telemedicine. DEA and HHS have repeatedly extended a temporary waiver of that requirement; the fourth extension runs through December 31, 2026. A permanent special registration rule was under federal review in late 2026. Confirm the current rule before prescribing a stimulant to a patient never seen in person.

Referral triggers

• Diagnostic uncertainty, especially with suspected autism spectrum disorder, learning disorders or intellectual disability.
• Coexisting bipolar disorder, psychosis, severe depression with suicidal ideation (give the 988 Suicide and Crisis Lifeline number), or active substance use disorder.
• Preschool children whose symptoms persist after behavioral treatment, when the provider is not experienced with medication at that age.
• Positive cardiac screen.
• Inadequate response after trials of both stimulant classes.
• Adults whose history does not establish onset before 12 or whose symptoms appear only in one setting.

Patient and family education

• ADHD is a chronic neurodevelopmental condition; medication treats symptoms but does not cure it.
• Give long-acting stimulants in the morning to protect sleep, and eat breakfast before the dose takes hold.
• Store stimulants locked, count them, and never share or sell them; this is a federal crime and a common route to misuse among teens and college students.
• Report chest pain, fainting, palpitations, new tics, mood changes or unusual thoughts.
• Behavioral strategies, routines and school accommodations remain part of the plan even when medication works.
• Teens: driving safety matters because untreated ADHD raises crash risk; coverage during evening driving is worth planning.

How the exam tests this

• The preschooler. A 4-year-old with ADHD symptoms: the first answer is PTBM, not methylphenidate.
• One setting only. Symptoms reported only at home or only at school do not meet criteria; gather a second informant before diagnosing.
• Onset after 12. An adult whose problems began in a demanding job at 30 needs another explanation first.
• Refill requests. "Add two refills to the stimulant" is always wrong; the correct answer is sequential prescriptions with fill dates up to a 90-day supply, if state law allows.
• Substance use history. A young adult with a recent stimulant use disorder: choose a nonstimulant such as atomoxetine.
• Tics. Stimulants can be used with tics, but an alpha-2 agonist is a reasonable choice when tics are the problem.
• Growth and blood pressure. Failure to plot height and weight or recheck blood pressure is the monitoring error.
• Routine ECG. Not required for every child; the answer is a cardiac history and examination.

Practice question

A 7-year-old boy is evaluated for ADHD. Vanderbilt rating scales from his mother and his teacher both show seven inattentive and six hyperactive-impulsive symptoms for more than a year, with failing grades and frequent classroom removals. Hearing and vision are normal. He has no history of syncope or chest pain, and there is no family history of sudden cardiac death. Blood pressure and cardiac examination are normal. Which of the following is the most appropriate management?

• A. Parent training in behavior management alone for 6 months before considering medication
• B. An FDA-approved stimulant titrated to effect, plus parent training and classroom behavioral supports with a 504 plan or IEP
• C. Obtain an ECG and echocardiogram before any treatment decision
• D. Extended-release clonidine as initial monotherapy because it is not a controlled substance

Answer: B. For a child aged 6 to 11 with ADHD confirmed from two settings, the AAP 2019 guideline recommends FDA-approved medication together with parent training and/or behavioral classroom interventions, preferably both, plus school supports. Option A is the first-line approach for preschoolers aged 4 to 5, not for a 7-year-old. Option C orders cardiac testing that is not indicated when the personal and family cardiac history and the examination are negative. Option D uses a drug with weaker evidence than stimulants as the first choice without a reason such as tics, substance misuse risk or stimulant intolerance.

Key points

Related NPPace guides

• Anxiety Disorders for the NP Exam: GAD-7, Panic, First-Line Drugs and When Benzodiazepines Are Wrong
• Depression in Primary Care: PHQ-9 Screening, Starting an SSRI and the Follow-Up Schedule
• Insomnia: Why CBT-I Comes First, Which Drugs When, and the Older-Adult Rules
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?